While lower concentrations of C4 and C9 compounds suppressed PLK1 overexpressing cancer cells more effectively (Figure 5B), compound C4 showed the best in vivo pharmacokinetic (PK) profile of the tested IGF2BP2 inhibitors. The gene discussed is PLK1; the disease is cancer.